Cure criteria and follow-up: 1. Growth hormone adenoma: random growth hormone level <1μg/L, IGF-I level decreased to normal range matching gender and age as the cure criteria. 2. PRL adenoma: PRL <20 μg/L in women and PRL <15 μg/L in men without dopamine agonists or other treatments, and PRL <10 μg/L on postoperative day 1 indicates a good prognosis. 3. ACTH adenoma: blood cortisol <20 μg/L within 2 d after surgery, 24 h urinary free cortisol and ACTH levels in normal range or below normal (UFC). Within 3-6 months after surgery, blood cortisol, 24-h urine free cortisol and ACTH were within normal range or below normal level, and clinical symptoms disappeared or resolved. 4. TSH, free T3 and free T4 levels decreased to normal within 2 d after TSH adenoma surgery. 5.The levels of FSH and LH decreased to normal within 2 d after surgery of gonadotropin adenoma. 6. No residual tumor on MRI 3-6 months after surgery for non-functional adenoma. For functional adenoma, normalization of hormone levels for more than 6 months after surgery is the baseline for cure; the first MRI examination is performed 3-4 months after surgery, and thereafter, the MRI examination can be repeated 3-6 months when the hormone levels and condition are as required, and once a year when the cure standard is reached. Pituitary hormone testing and other related examinations, such as visual acuity and visual field, will be performed on the first postoperative day and at the time of discharge, and the changes in symptoms and signs will be recorded in detail. Early (within 1 week after surgery) pituitary enhancement MRI is recommended. When patients are discharged from the hospital, health education is emphasized, and the importance of long-term follow-up is instructed to control their disease and improve the quality of survival, and follow-up cards are given to inform the follow-up process. Patients will receive annual follow-up questionnaires and will inform the follow-up physician of any changes in address or telephone number. Pituitary hormone and related tests will be performed from the 6th to the 12th week after surgery to assess the function of pituitary and each target gland. Patients with pituitary dysfunction were given the appropriate hormone replacement therapy, and patients with complications were followed up with the appropriate tests. Pituitary MRI was reviewed 3 months after surgery to assess postoperative imaging changes and to document changes in patient symptoms and signs. For patients with pituitary dysfunction requiring hormone replacement therapy, monthly follow-up of symptoms, signs and hormone levels should be performed to record the changes and adjust the replacement therapy in a timely manner. After the patient’s condition stabilizes, pituitary and target gland functions can be evaluated every 3 months, and hormone replacement therapy can be adjusted according to the follow-up results. Some patients require lifelong hormone replacement therapy.